Program
UI059
A development code.
Its studies are mostly in Gastroesophageal Reflux · Digestive System Diseases, led by Korea United Pharm..
Furthest: phase 1, since Nov 15, 20233 company-led studies, 2 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Korea United Pharm. | 32 open or running | phase 1since Nov 15, 2023 | Nov 15, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 15, 2023First study: phase 1 study in Gastroesophageal RefluxFirst studyNCT06141577 · 8 enrolled · Korea, Republic of
- Apr 28, 2024Phase 1 study in Digestive System DiseasesNCT06393881 · 66 planned · Korea, Republic of
- Jun 18, 2026Phase 1 study in Gastro Esophageal Reflux DisorderNCT07727629 · 60 planned · South Korea
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07727629Gastro Esophageal Reflux Disorder · South Korea | 1 | Not yet recruiting | Aug 2026 | 60 |
| NCT06393881Digestive System Diseases · Korea, Republic of | 1 | Not yet recruiting | Sep 14, 2024 | 66 |
| NCT06141577Gastroesophageal Reflux · Korea, Republic of | 1 | Completed | Nov 7, 2023 | 8 |
How it is read
Names in the registry
- “UI059”, 3 entries
Codes read as this program: UI059.
Conditions, from the studies’ own filings
- Gastroesophageal Reflux, 2 studies
- Digestive System Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.